Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Wüllner U[au]:

Search results

Items: 1 to 50 of 206

1.

Common genetic variants associated with Parkinson's disease display widespread signature of epigenetic plasticity.

Sharma A, Osato N, Liu H, Asthana S, Dakal TC, Ambrosini G, Bucher P, Schmitt I, Wüllner U.

Sci Rep. 2019 Dec 5;9(1):18464. doi: 10.1038/s41598-019-54865-w.

2.

Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT; AETIONOMY study group.

Alzheimers Dement. 2019 Oct 17. pii: S1552-5260(19)35352-X. doi: 10.1016/j.jalz.2019.07.018. [Epub ahead of print]

3.

Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras.

Nachreiner I, Hussain AF, Wullner U, Machuy N, Meyer TF, Fischer R, Gattenlöhner S, Meinhold-Heerlein I, Barth S, Tur MK.

Exp Ther Med. 2019 Oct;18(4):2401-2412. doi: 10.3892/etm.2019.7753. Epub 2019 Jul 9.

4.

α-Synuclein in Parkinson's disease: causal or bystander?

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM.

J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25. Review.

PMID:
31240402
5.

Polypharmacy in Parkinson's disease: risks and benefits with little evidence.

Csoti I, Herbst H, Urban P, Woitalla D, Wüllner U.

J Neural Transm (Vienna). 2019 Jul;126(7):871-878. doi: 10.1007/s00702-019-02026-8. Epub 2019 Jun 20.

PMID:
31222606
6.

Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD.

de Boni L, Wüllner U.

Front Neurosci. 2019 Apr 5;13:276. doi: 10.3389/fnins.2019.00276. eCollection 2019.

7.

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.

Hopfner F, Müller SH, Steppat D, Miller J, Schmidt N, Wandinger KP, Leypoldt F, Berg D, Franke A, Lieb W, Tittmann L, Balzer-Geldsetzer M, Baudrexel S, Dodel R, Hilker-Roggendorf R, Kalbe E, Kassubek J, Klockgether T, Liepelt-Scarfone I, Mollenhauer B, Neuser P, Reetz K, Riedel O, Schulte C, Schulz JB, Spottke A, Storch A, Trenkwalder C, Wittchen HU, Witt K, Wüllner U, Deuschl G, Kuhlenbäumer G.

Transl Neurodegener. 2019 Apr 3;8:11. doi: 10.1186/s40035-019-0153-0. eCollection 2019.

8.

5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinson's disease.

Kaut O, Kuchelmeister K, Moehl C, Wüllner U.

J Chem Neuroanat. 2019 Mar;96:41-48. doi: 10.1016/j.jchemneu.2018.12.005. Epub 2018 Dec 14.

PMID:
30557654
9.

[Magnetic resonance-guided focused ultrasound : A new option for tremor treatment].

Purrer V, Keil VC, Grötz S, Hamed M, Upadhyay N, Faber J, Boecker H, Borger V, Pieper C, Wüllner U.

Nervenarzt. 2019 Apr;90(4):408-411. doi: 10.1007/s00115-018-0627-9. German. No abstract available.

PMID:
30406441
10.

Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition.

Wojtala J, Heber IA, Neuser P, Heller J, Kalbe E, Rehberg SP, Storch A, Linse K, Schneider C, Gräber S, Berg D, Dams J, Balzer-Geldsetzer M, Hilker-Roggendorf R, Oberschmidt C, Baudrexel S, Witt K, Schmidt N, Deuschl G, Mollenhauer B, Trenkwalder C, Liepelt-Scarfone I, Spottke A, Roeske S, Wüllner U, Wittchen HU, Riedel O, Dodel R, Schulz JB, Reetz K.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):171-179. doi: 10.1136/jnnp-2018-319008. Epub 2018 Oct 8.

PMID:
30297519
11.

A stably self-renewing adult blood-derived induced neural stem cell exhibiting patternability and epigenetic rejuvenation.

Sheng C, Jungverdorben J, Wiethoff H, Lin Q, Flitsch LJ, Eckert D, Hebisch M, Fischer J, Kesavan J, Weykopf B, Schneider L, Holtkamp D, Beck H, Till A, Wüllner U, Ziller MJ, Wagner W, Peitz M, Brüstle O.

Nat Commun. 2018 Oct 2;9(1):4047. doi: 10.1038/s41467-018-06398-5.

12.

[Nutritional aspects in Parkinson's disease: disease risk, dietary therapy and treatment of digestive tract dysfunction].

Csoti I, Dresel C, Hauptmann B, Müller T, Redecker C, Warnecke T, Wüllner U.

Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S34-S42. doi: 10.1055/a-0681-6700. Epub 2018 Sep 21. Review. German.

PMID:
30241099
13.

[The gut microbiome in Parkinson's disease].

Bedarf JR, Hildebrand F, Goeser F, Bork P, Wüllner U.

Nervenarzt. 2019 Feb;90(2):160-166. doi: 10.1007/s00115-018-0601-6. Review. German.

PMID:
30171304
14.

DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling.

de Boni L, Gasparoni G, Haubenreich C, Tierling S, Schmitt I, Peitz M, Koch P, Walter J, Wüllner U, Brüstle O.

Clin Epigenetics. 2018 Jan 29;10:13. doi: 10.1186/s13148-018-0440-0. eCollection 2018.

15.

DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis.

Piston D, Alvarez-Erviti L, Bansal V, Gargano D, Yao Z, Szabadkai G, Odell M, Puno MR, Björkblom B, Maple-Grødem J, Breuer P, Kaut O, Larsen JP, Bonn S, Møller SG, Wüllner U, Schapira AHV, Gegg ME.

Hum Mol Genet. 2018 Feb 1;27(3):576. doi: 10.1093/hmg/ddx425. No abstract available.

16.

DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis.

Piston D, Alvarez-Erviti L, Bansal V, Gargano D, Yao Z, Szabadkai G, Odell M, Puno MR, Björkblom B, Maple-Grødem J, Breuer P, Kaut O, Larsen JP, Bonn S, Møller SG, Wüllner U, Schapira AHV, Gegg ME.

Hum Mol Genet. 2017 Oct 15;26(20):4028-4041. doi: 10.1093/hmg/ddx294. Erratum in: Hum Mol Genet. 2018 Feb 1;27(3):576.

17.

Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.

Classen J, Koschel J, Oehlwein C, Seppi K, Urban P, Winkler C, Wüllner U, Storch A.

J Neural Transm (Vienna). 2017 Aug;124(8):1029-1036. doi: 10.1007/s00702-017-1757-0. Epub 2017 Jul 12. Review.

PMID:
28702850
18.

Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females.

Sharma A, Kaut O, Pavlova A, Fröhlich H, Ahmad A, Schmitt I, El-Maarri O, Oldenburg J, Wüllner U.

Neurobiol Aging. 2017 Sep;57:248.e1-248.e5. doi: 10.1016/j.neurobiolaging.2017.05.021. Epub 2017 Jun 6.

PMID:
28663000
19.

Erratum to: Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.

Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P, Wüllner U.

Genome Med. 2017 Jun 29;9(1):61. doi: 10.1186/s13073-017-0451-z. No abstract available.

20.

DNA methylation of DLG4 and GJA-1 of human hippocampus and prefrontal cortex in major depression is unchanged in comparison to healthy individuals.

Kaut O, Sharma A, Schmitt I, Hurlemann R, Wüllner U.

J Clin Neurosci. 2017 Sep;43:261-263. doi: 10.1016/j.jocn.2017.05.030. Epub 2017 Jun 20.

PMID:
28645745
21.

Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients.

Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P, Wüllner U.

Genome Med. 2017 Apr 28;9(1):39. doi: 10.1186/s13073-017-0428-y. Erratum in: Genome Med. 2017 Jun 29;9(1):61.

22.

Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein.

Noronha C, Perfeito R, Laço M, Wüllner U, Rego AC.

Neurochem Res. 2017 May;42(5):1430-1437. doi: 10.1007/s11064-017-2199-7. Epub 2017 Feb 25.

PMID:
28236214
23.

DNA methylation of imprinted loci of autosomal chromosomes and IGF2 is not affected in Parkinson's disease patients' peripheral blood mononuclear cells.

Kaut O, Sharma A, Schmitt I, Wüllner U.

Neurol Res. 2017 Mar;39(3):281-284. doi: 10.1080/01616412.2017.1279424. Epub 2017 Jan 12.

PMID:
28081695
24.

The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53.

Liu H, Li X, Ning G, Zhu S, Ma X, Liu X, Liu C, Huang M, Schmitt I, Wüllner U, Niu Y, Guo C, Wang Q, Tang TS.

PLoS Biol. 2016 Nov 16;14(11):e2000733. doi: 10.1371/journal.pbio.2000733. eCollection 2016 Nov.

25.

A genome-wide association study in multiple system atrophy.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.

Neurology. 2016 Oct 11;87(15):1591-1598. Epub 2016 Sep 14.

26.

Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinson's disease revealed different epigenetic patterns in peripheral blood mononuclear cells.

Kaut O, Schmitt I, Tost J, Busato F, Liu Y, Hofmann P, Witt SH, Rietschel M, Fröhlich H, Wüllner U.

Neurogenetics. 2017 Jan;18(1):7-22. doi: 10.1007/s10048-016-0497-x. Epub 2016 Oct 6.

PMID:
27709425
27.

Stochastic resonance therapy induces increased movement related caudate nucleus activity.

Kaut O, Becker B, Schneider C, Zhou F, Fliessbach K, Hurlemann R, Wüllner U.

J Rehabil Med. 2016 Oct 12;48(9):815-818. doi: 10.2340/16501977-2143.

28.

Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease.

Mengel D, Dams J, Ziemek J, Becker J, Balzer-Geldsetzer M, Hilker R, Baudrexel S, Kalbe E, Schmidt N, Witt K, Liepelt-Scarfone I, Gräber S, Petrelli A, Neuser P, Schulte C, Linse K, Storch A, Wittchen HU, Riedel O, Mollenhauer B, Ebentheuer J, Trenkwalder C, Klockgether T, Spottke A, Wüllner U, Schulz JB, Reetz K, Heber IA, Ramirez A, Dodel R.

Parkinsonism Relat Disord. 2016 Aug;29:112-6. doi: 10.1016/j.parkreldis.2016.04.013. Epub 2016 Apr 19.

PMID:
27321987
29.

[Epigenetics in Parkinson's Disease].

Wüllner U.

Fortschr Neurol Psychiatr. 2016 Jul;84 Suppl 1:S3-7. doi: 10.1055/s-0042-104501. Epub 2016 Jun 14. Review. German.

PMID:
27299943
30.

Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumab-A Case Report.

Schäfer N, Müller A, Wüllner U.

J Stroke Cerebrovasc Dis. 2016 Aug;25(8):e126-7. doi: 10.1016/j.jstrokecerebrovasdis.2016.05.006. Epub 2016 May 25.

PMID:
27236361
31.

DNA methylation in Parkinson's disease.

Wüllner U, Kaut O, deBoni L, Piston D, Schmitt I.

J Neurochem. 2016 Oct;139 Suppl 1:108-120. doi: 10.1111/jnc.13646. Epub 2016 Jun 10. Review.

32.

Postural Stability in Parkinson's Disease Patients Is Improved after Stochastic Resonance Therapy.

Kaut O, Brenig D, Marek M, Allert N, Wüllner U.

Parkinsons Dis. 2016;2016:7948721. doi: 10.1155/2016/7948721. Epub 2016 Jan 26.

33.

Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.

Bernis ME, Babila JT, Breid S, Wüsten KA, Wüllner U, Tamgüney G.

Acta Neuropathol Commun. 2015 Nov 26;3:75. doi: 10.1186/s40478-015-0254-7.

34.

DNA methylation levels of α-synuclein intron 1 in the aging brain.

de Boni L, Riedel L, Schmitt I, Kraus TFJ, Kaut O, Piston D, Akbarian S, Wüllner U.

Neurobiol Aging. 2015 Dec;36(12):3334.e7-3334.e11. doi: 10.1016/j.neurobiolaging.2015.08.028. Epub 2015 Sep 8.

PMID:
26422361
35.

PDON: Parkinson's disease ontology for representation and modeling of the Parkinson's disease knowledge domain.

Younesi E, Malhotra A, Gündel M, Scordis P, Kodamullil AT, Page M, Müller B, Springstubbe S, Wüllner U, Scheller D, Hofmann-Apitius M.

Theor Biol Med Model. 2015 Sep 22;12:20. doi: 10.1186/s12976-015-0017-y.

36.

L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.

Schmitt I, Kaut O, Khazneh H, deBoni L, Ahmad A, Berg D, Klein C, Fröhlich H, Wüllner U.

Mov Disord. 2015 Nov;30(13):1794-801. doi: 10.1002/mds.26319. Epub 2015 Jul 14.

PMID:
26173746
37.

Variants associated with Gaucher disease in multiple system atrophy.

Mitsui J, Matsukawa T, Sasaki H, Yabe I, Matsushima M, Dürr A, Brice A, Takashima H, Kikuchi A, Aoki M, Ishiura H, Yasuda T, Date H, Ahsan B, Iwata A, Goto J, Ichikawa Y, Nakahara Y, Momose Y, Takahashi Y, Hara K, Kakita A, Yamada M, Takahashi H, Onodera O, Nishizawa M, Watanabe H, Ito M, Sobue G, Ishikawa K, Mizusawa H, Kanai K, Hattori T, Kuwabara S, Arai K, Koyano S, Kuroiwa Y, Hasegawa K, Yuasa T, Yasui K, Nakashima K, Ito H, Izumi Y, Kaji R, Kato T, Kusunoki S, Osaki Y, Horiuchi M, Kondo T, Murayama S, Hattori N, Yamamoto M, Murata M, Satake W, Toda T, Filla A, Klockgether T, Wüllner U, Nicholson G, Gilman S, Tanner CM, Kukull WA, Stern MB, Lee VM, Trojanowski JQ, Masliah E, Low PA, Sandroni P, Ozelius LJ, Foroud T, Tsuji S.

Ann Clin Transl Neurol. 2015 Apr;2(4):417-26. doi: 10.1002/acn3.185. Epub 2015 Feb 28.

38.

Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression.

Kaut O, Schmitt I, Hofmann A, Hoffmann P, Schlaepfer TE, Wüllner U, Hurlemann R.

Eur Arch Psychiatry Clin Neurosci. 2015 Jun;265(4):331-41. doi: 10.1007/s00406-014-0572-y. Epub 2015 Jan 9.

PMID:
25571874
39.

DNA methylation of the TNF-α promoter region in peripheral blood monocytes and the cortex of human Alzheimer's disease patients.

Kaut O, Ramirez A, Pieper H, Schmitt I, Jessen F, Wüllner U.

Dement Geriatr Cogn Disord. 2014;38(1-2):10-5. doi: 10.1159/000357126. Epub 2014 Feb 19.

PMID:
24556805
40.

Reply to: Cognitive dysfunction in spinocerebellar ataxia type 3: variable topographies and patterns.

Roeske S, Filla I, Heim S, Amunts K, Helmstaedter C, Wüllner U, Wagner M, Klockgether T, Minnerop M.

Mov Disord. 2014 Jan;29(1):157-8. doi: 10.1002/mds.25755. Epub 2013 Dec 11. No abstract available.

PMID:
24338591
41.

Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans.

Striepens N, Kendrick KM, Hanking V, Landgraf R, Wüllner U, Maier W, Hurlemann R.

Sci Rep. 2013 Dec 6;3:3440. doi: 10.1038/srep03440.

42.

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Yue X, Hariri DJ, Caballero B, Zhang S, Bartlett MJ, Kaut O, Mount DW, Wüllner U, Sherman SJ, Falk T.

Neuroscience. 2014 Jan 31;258:385-400. doi: 10.1016/j.neuroscience.2013.11.038. Epub 2013 Nov 27.

43.

A randomized pilot study of stochastic vibration therapy in spinocerebellar ataxia.

Kaut O, Jacobi H, Coch C, Prochnicki A, Minnerop M, Klockgether T, Wüllner U.

Cerebellum. 2014 Apr;13(2):237-42. doi: 10.1007/s12311-013-0532-5.

PMID:
24197754
44.

Patient selection for mechanical thrombectomy.

Nelles M, Greschus S, Möhlenbruch M, Simon B, Wüllner U, Urbach H.

Clin Neuroradiol. 2014 Sep;24(3):239-44. doi: 10.1007/s00062-013-0237-7. Epub 2013 Oct 17.

PMID:
24132553
45.

Progressive cognitive dysfunction in spinocerebellar ataxia type 3.

Roeske S, Filla I, Heim S, Amunts K, Helmstaedter C, Wüllner U, Wagner M, Klockgether T, Minnerop M.

Mov Disord. 2013 Sep;28(10):1435-8. doi: 10.1002/mds.25512. Epub 2013 Jun 4.

PMID:
23736996
46.

No association of GBA mutations and multiple system atrophy.

Srulijes K, Hauser AK, Guella I, Asselta R, Brockmann K, Schulte C, Soldà G, Cilia R, Maetzler W, Schols L, Wenning GK, Poewe W, Barone P, Wüllner U, Oertel W, Berg D, Goldwurm S, Gasser T.

Eur J Neurol. 2013 Apr;20(4):e61-2. doi: 10.1111/ene.12086. No abstract available.

PMID:
23490118
47.

A possible genetic link between MTHFR genotype and smoking behavior.

Linnebank M, Moskau S, Semmler A, Hoefgen B, Bopp G, Kallweit U, Maier W, Schütz CG, Wüllner U.

PLoS One. 2012;7(12):e53322. doi: 10.1371/journal.pone.0053322. Epub 2012 Dec 28.

48.

Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).

Hübener J, Weber JJ, Richter C, Honold L, Weiss A, Murad F, Breuer P, Wüllner U, Bellstedt P, Paquet-Durand F, Takano J, Saido TC, Riess O, Nguyen HP.

Hum Mol Genet. 2013 Feb 1;22(3):508-18. doi: 10.1093/hmg/dds449. Epub 2012 Oct 24.

PMID:
23100324
49.

Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey.

Wüllner U, Fuchs G, Reketat N, Randerath O, Kassubek J.

Curr Med Res Opin. 2012 Jul;28(7):1239-46. doi: 10.1185/03007995.2012.702101. Epub 2012 Jun 26.

PMID:
22686959
50.

Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.

Schmitt I, Wüllner U, van Rooyen JP, Khazneh H, Becker J, Volk A, Kubisch C, Becker T, Kostic VS, Klein C, Ramirez A.

Eur J Hum Genet. 2012 Dec;20(12):1265-9. doi: 10.1038/ejhg.2012.84. Epub 2012 May 23.

Supplemental Content

Loading ...
Support Center